Biotech Stock Falls on Late-Stage Study

FibroGen's neuromuscular disorder therapy failed to meet expectations

Deputy Editor
Jun 7, 2023 at 10:29 AM
facebook twitter linkedin

FibroGen Inc (NASDAQ:FGEN) stock is sliding today, after the biotech company announced disappointing results from a late-stage trial of pamrevlumab, its experimental drug to treat patients with Duchenne muscular dystrophy. At last glance, FGEN was down 9% to trade at $17.02. 

The stock's 80-day moving average kept a cap on gains the last couple sessions, and the stock is now back below the $18 level, which provided a firm line of pressure for most of May. Year-over-year, the equity is up about 65%. 

It's also worth noting that short interest represents 6.2% of the stock's available float. It would take shorts over six days to cover their bets, at FGEN's average pace of trading. 

Short-term options traders have been much more bearish than usual, per the stock's Schaeffer's put/call open interest ratio (SOIR) of 1.20, which sits in the 100th percentile of readings from the past 12 months.


Now is the time to join our thriving community of Event Traders who consistently profit from every earnings season. With this discounted subscription opportunity, you'll stay ahead of the curve and seize opportunities others miss. Do not let Q3 earnings season pass you by – subscribe now and supercharge your portfolio with expert insights that turn market reactions into profit-generating opportunities!! Don't waste another second... join us right now before the next trade targeting +200% is released!